Abstract 921P
Background
Incidence of oropharyngeal squamous cell carcinoma (OPSCC) increases due to rise in human papilloma virus (HPV) related cancers. The tumor microenvironment (TME) of HPV+ OPSCC is characterized as more immune tolerant, with higher density of tumor-infiltrating lymphocytes (TILs). The role of tumor-associated macrophages (TAMs) remains unclear. M2-like TAMs are correlated with impaired overall survival (OS) in other tumor types. This study characterizes the prognostic impact of M2-like TAMs in OPSCC.
Methods
Fifty-eight patients with primary OPSCC, undergoing definite treatment (surgery, radiotherapy, chemoradiotherapy or a combination), were included. FFPE samples were stained for P16, TILs (CD3, CD8, FOXP3) and TAMs (CD68, CD163 and CD206) markers. Semi-quantitative assessment of each marker, in the tumor nest(t) and stroma(s), was executed by a board certified pathologist. Survival estimates were calculated via the Kaplan-Meier method using the log-rank test, using the ad hoc calculated cut-off point. Uni- and multivariate analysis were performed via cox proportional hazard model.
Results
The median density of sCD3, sCD8, tCD68 and sCD206 TAMs was higher in P16+, compared to P16–, whereas FOXP3 and CD163 infiltration was similar according to P16 status. In univariate analysis, tumors with high leukocyte infiltrates (sTIL, sCD8, tCD8, sFOXP3, tCD68, sCD206) had a better overall survival (OS), whereas sTIL-high and tCD8-high were the only factors associated with DFS. High tCD68 (HR 0.19) and sCD206 (HR 0.40) were associated with improved OS in P16+ OPSCC, but not in P16-. sCD163 and tCD163 infiltration was not related to adverse outcomes in P16+ nor in P16-. Table: 921P
Clinical and immunohistochemical characteristics
| P16- | P16+ | p value | |
| N | 39 | 19 | |
| mean Age (y, SD) | 58.8y (8.0) | 59.8y (8.8) | 0.65 |
| mDFS (months, 95%CI) | 14.4m (7.8-48)* | 158m (30-NR)* | ConclusionsIn this study, high tCD68 and sCD206 expression was associated with a better OS in OPSCC, albeit only in P16+ tumors. No concordance was found between CD163 and CD206 expression and both had a different prognostic impact. This illustrates the complexity of TIL-TAM interplay and the TAM spectrum diversity. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyGhent University Hospital. FundingGhent University Hospital Fonds voor Innovatie en Klinisch Onderzoek (FIKO). DisclosureM. Saerens: Financial Interests, Institutional, Invited Speaker: Pierre-Fabre, BMS, MSD; Financial Interests, Institutional, Advisory Board: Novartis, MSD. S. Rottey: Financial Interests, Institutional, Advisory Board: Pfizer, Merck, Roche, Ipsen, BMS; Financial Interests, Institutional, Invited Speaker: Ipsen, BMS, Astellas; Financial Interests, Institutional, Research Grant: MSD, Roche, BMS; Non-Financial Interests, Principal Investigator, It is my main task in the hospital to attract and perform clinical trials in oncology phase I-III: all companies performing clinical trials in oncology in Europe. All other authors have declared no conflicts of interest. Resources from the same session917P - Automatic characterization of spatial arrangement of tumor-infiltrating lymphocytes identifies oral cavity squamous cell carcinoma patients with poorer prognosisPresenter: German Corredor Session: Poster session 03 918P - Deciphering the molecular drivers behind locoregional progression, intratumoral heterogeneity, and clonal evolution in locally advanced head and neck cancerPresenter: Gema Bruixola Session: Poster session 03 919P - Predictive multi-omic signature in locally advanced laryngeal/hypopharyngeal (LH) squamous cell carcinoma (SCC) treated with induction chemotherapy (IC)Presenter: Paolo Bossi Session: Poster session 03 920P - Genomic landscape of head and neck cancer in Asia: A comprehensive meta-analysis of 1016 samplesPresenter: Sewanti Limaye Session: Poster session 03 Resources: Abstract 922P - Genomic instability as a biomarker for advanced cancer of the head and neckPresenter: Filippo Dall'Olio Session: Poster session 03 923P - Tumor-informed ctDNA assay to predict recurrence in locally advanced SCCHNPresenter: Natasha Honoré Session: Poster session 03 924P - Claudin-1 (CLDN1) tight junction protein expression delineates distinct immune infiltrates in ascending (A) vs descending (D) subtypes of nasopharyngeal carcinoma: Potential implications for treatment selectionPresenter: Darren Wan-Teck Lim Session: Poster session 03 925P - External validation of the CD8 radiomics signature as a prognostic marker in recurrent or metastatic head and neck cancer treated with nivolumabPresenter: Laville Adrien Session: Poster session 03 926P - Genetic alteration in olfactory neuroblastoma: Unraveling carcinogenesis mechanisms and chemotherapy resistance through whole exome sequencing analysisPresenter: Haruhi Furukawa Session: Poster session 03 927P - Preliminary results of the BROADEN study: Burden of human papillomavirus-related head and neck cancersPresenter: Laia Alemany Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|